The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Drug Delivery Systems

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Drug Delivery Systems

  • The purpose of this study was to determine if the sustained release of ampicillin from a biodegradable drug-delivery system (microencapsulated ampicillin anhydrate (MEAA)) will increase or decrease the intensity of a hypersensitivity reaction compared with that observed with free drug [1].
  • In this report, we describe a pilot safety and efficacy trial of a novel sustained drug delivery system containing fluocinolone acetonide to treat patients with severe uveitis [2].
  • CONCLUSIONS: MB M036, derived from phage display selected species crossreactive scFv, is suitable for tumor stroma targeting and will be a valuable tool in the analyses of the functional role of FAP in tumor biology as well as in the evaluation of the suitability of FAP for drug targeting [3].
  • The tubulin inhibitor combretastatin A-4 disodium phosphate (CA-4) is a new vascular targeting drug which displays a low toxicity profile [4].
  • With the aim of developing an effective therapeutic modality for treatment of thrombosis, a tissue-type plasminogen activator (t-PA)-loaded porous poly(L-glutamic acid) (PLGA) semi-interpenetrating polymer network (semi-IPN) hydrogel was developed as a possible local drug delivery system [5].
 

Psychiatry related information on Drug Delivery Systems

 

High impact information on Drug Delivery Systems

  • Because expression of ALOX5 is in part transcriptionally regulated, we reasoned that patients with these sequence variants may have diminished gene transcription, and therefore decreased ALOX5 product production and a diminished clinical response to treatment with a drug targeting this pathway [8].
  • Our observations support the use of antibodies in the prevention and treatment of prion diseases and identify a region of PrPC for drug targeting [9].
  • Glycocalix[4]arenes show the phenomenon of multivalency in their binding to specific lectins, and those bearing thiourea spacers between the calix[4]arene scaffold and the sugar units are able to bind aromatic carboxylates and phosphates, making them attractive as novel site specific drug delivery systems [10].
  • Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting [11].
  • Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity [12].
 

Chemical compound and disease context of Drug Delivery Systems

 

Biological context of Drug Delivery Systems

 

Anatomical context of Drug Delivery Systems

 

Associations of Drug Delivery Systems with chemical compounds

 

Gene context of Drug Delivery Systems

 

Analytical, diagnostic and therapeutic context of Drug Delivery Systems

References

  1. Evaluation of hypersensitivity to microencapsulated ampicillin in guinea pigs. Barsoum, I.S., Kopydlowski, K.M., Cuenin, P., Setterstrom, J.A. J. Antimicrob. Chemother. (1997) [Pubmed]
  2. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Jaffe, G.J., Ben-Nun, J., Guo, H., Dunn, J.P., Ashton, P. Ophthalmology (2000) [Pubmed]
  3. Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse. Brocks, B., Garin-Chesa, P., Behrle, E., Park, J.E., Rettig, W.J., Pfizenmaier, K., Moosmayer, D. Mol. Med. (2001) [Pubmed]
  4. Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors. Eikesdal, H.P., Bjerkvig, R., Mella, O., Dahl, O. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. (2001) [Pubmed]
  5. Controlled release of clot-dissolving tissue-type plasminogen activator from a poly(L-glutamic acid) semi-interpenetrating polymer network hydrogel. Park, Y., Liang, J., Yang, Z., Yang, V.C. Journal of controlled release : official journal of the Controlled Release Society. (2001) [Pubmed]
  6. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I.v. effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats. Fujisaki, J., Tokunaga, Y., Takahashi, T., Shimojo, F., Kimura, S., Hata, T. Journal of drug targeting. (1998) [Pubmed]
  7. Simple and sensitive method for determination of nicotine in plasma by gas chromatography. Nyström, L., Pettersson, M., Rångemark, C. J. Chromatogr. B Biomed. Sci. Appl. (1997) [Pubmed]
  8. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Drazen, J.M., Yandava, C.N., Dubé, L., Szczerback, N., Hippensteel, R., Pillari, A., Israel, E., Schork, N., Silverman, E.S., Katz, D.A., Drajesk, J. Nat. Genet. (1999) [Pubmed]
  9. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Peretz, D., Williamson, R.A., Kaneko, K., Vergara, J., Leclerc, E., Schmitt-Ulms, G., Mehlhorn, I.R., Legname, G., Wormald, M.R., Rudd, P.M., Dwek, R.A., Burton, D.R., Prusiner, S.B. Nature (2001) [Pubmed]
  10. Peptido- and glycocalixarenes: playing with hydrogen bonds around hydrophobic cavities. Casnati, A., Sansone, F., Ungaro, R. Acc. Chem. Res. (2003) [Pubmed]
  11. Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting. Kamada, H., Tsutsumi, Y., Sato-Kamada, K., Yamamoto, Y., Yoshioka, Y., Okamoto, T., Nakagawa, S., Nagata, S., Mayumi, T. Nat. Biotechnol. (2003) [Pubmed]
  12. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Adlakha-Hutcheon, G., Bally, M.B., Shew, C.R., Madden, T.D. Nat. Biotechnol. (1999) [Pubmed]
  13. A randomised controlled trial evaluating a novel cytotoxic drug delivery system for the treatment of cervical intraepithelial neoplasia. Sidhu, H.K., Price, J.H., McCarron, P.A., McCafferty, D.F., Woolfson, A.D., Biggart, D., Thompson, W. British journal of obstetrics and gynaecology. (1997) [Pubmed]
  14. Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. Choe, Y.H., Conover, C.D., Wu, D., Royzen, M., Gervacio, Y., Borowski, V., Mehlig, M., Greenwald, R.B. Journal of controlled release : official journal of the Controlled Release Society. (2002) [Pubmed]
  15. Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats. Suhara, H., Sawa, Y., Fukushima, N., Kagisaki, K., Yokoyama, C., Tanabe, T., Ohtake, S., Matsuda, H. J. Thorac. Cardiovasc. Surg. (2002) [Pubmed]
  16. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Geller, D.E., Rosenfeld, M., Waltz, D.A., Wilmott, R.W. Chest (2003) [Pubmed]
  17. Receptor-mediated targeting of lipobeads bearing acetohydroxamic acid for eradication of Helicobacter pylori. Umamaheshwari, R.B., Jain, N.K. Journal of controlled release : official journal of the Controlled Release Society. (2004) [Pubmed]
  18. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Pakunlu, R.I., Wang, Y., Tsao, W., Pozharov, V., Cook, T.J., Minko, T. Cancer Res. (2004) [Pubmed]
  19. Leu-574 of HIF-1alpha is essential for the von Hippel-Lindau (VHL)-mediated degradation pathway. Huang, L.E., Pete, E.A., Schau, M., Milligan, J., Gu, J. J. Biol. Chem. (2002) [Pubmed]
  20. Adenosine A(1) receptor: analysis of the potential therapeutic effects obtained by its activation in the central nervous system. Dalpiaz, A., Manfredini, S. Current medicinal chemistry. (2002) [Pubmed]
  21. PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Christofidou-Solomidou, M., Scherpereel, A., Wiewrodt, R., Ng, K., Sweitzer, T., Arguiri, E., Shuvaev, V., Solomides, C.C., Albelda, S.M., Muzykantov, V.R. Am. J. Physiol. Lung Cell Mol. Physiol. (2003) [Pubmed]
  22. HPMA-hydrogels containing cytostatic drugs. Kinetics of the drug release and in vivo efficacy. St'astný, M., Plocová, D., Etrych, T., Kovár, M., Ulbrich, K., Ríhová, B. Journal of controlled release : official journal of the Controlled Release Society. (2002) [Pubmed]
  23. Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate. Everts, M., Kok, R.J., Asgeirsdóttir, S.A., Melgert, B.N., Moolenaar, T.J., Koning, G.A., van Luyn, M.J., Meijer, D.K., Molema, G. J. Immunol. (2002) [Pubmed]
  24. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. Lee, H.J., Zhang, Y., Zhu, C., Duff, K., Pardridge, W.M. J. Cereb. Blood Flow Metab. (2002) [Pubmed]
  25. Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. Muzykantov, V.R., Murciano, J.C., Taylor, R.P., Atochina, E.N., Herraez, A. Anal. Biochem. (1996) [Pubmed]
  26. Enhanced in vitro oligonucleotide and plasmid DNA transport by VP1 virus-like particles. Henke, S., Rohmann, A., Bertling, W.M., Dingermann, T., Zimmer, A. Pharm. Res. (2000) [Pubmed]
  27. Lectin-mediated drug targeting: preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated doxorubicin on Caco-2 cells. Wirth, M., Fuchs, A., Wolf, M., Ertl, B., Gabor, F. Pharm. Res. (1998) [Pubmed]
  28. Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Muzykantov, V.R., Christofidou-Solomidou, M., Balyasnikova, I., Harshaw, D.W., Schultz, L., Fisher, A.B., Albelda, S.M. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  29. Brain drug delivery of small molecules using immunoliposomes. Huwyler, J., Wu, D., Pardridge, W.M. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  30. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Eliaz, R.E., Nir, S., Marty, C., Szoka, F.C. Cancer Res. (2004) [Pubmed]
  31. Phase I trial of an implanted battery-powered, programmable drug delivery system for continuous doxorubicin administration. Vogelzang, N.J., Ruane, M., DeMeester, T.R. J. Clin. Oncol. (1985) [Pubmed]
  32. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Lübbe, A.S., Bergemann, C., Riess, H., Schriever, F., Reichardt, P., Possinger, K., Matthias, M., Dörken, B., Herrmann, F., Gürtler, R., Hohenberger, P., Haas, N., Sohr, R., Sander, B., Lemke, A.J., Ohlendorf, D., Huhnt, W., Huhn, D. Cancer Res. (1996) [Pubmed]
  33. Selective abolition of pancreatic RNase binding to its inhibitor protein. Kumar, K., Brady, M., Shapiro, R. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  34. Apotransferrin is internalized and distributed in the same way as holotransferrin in K562 cells. Xiu-Lian, D., Kui, W., Ya, K., Lan, Y., Rong-Chang, L., Yan Zhong, C., Kwok Ping, H., Zhong Ming, Q. J. Cell. Physiol. (2004) [Pubmed]
  35. Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells. Yusuf-Makagiansar, H., Siahaan, T.J. Pharm. Res. (2001) [Pubmed]
  36. Intestinal drug delivery systems with biodegradable microspheres targeting mucosal immune-regulating cells for chronic inflammatory colitis. Okazaki, K., Nakase, H., Watanabe, N., Tabata, Y., Ikada, Y., Chiba, T. J. Gastroenterol. (2002) [Pubmed]
  37. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. Li, Z., Zhao, R., Wu, X., Sun, Y., Yao, M., Li, J., Xu, Y., Gu, J. FASEB J. (2005) [Pubmed]
  38. Spontaneous immobilization of liposomes on electron-beam exposed resist surfaces. Kim, J.M., Jung, H.S., Park, J.W., Yukimasa, T., Oka, H., Lee, H.Y., Kawai, T. J. Am. Chem. Soc. (2005) [Pubmed]
  39. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. Ul-Ain, Q., Sharma, S., Khuller, G.K. Antimicrob. Agents Chemother. (2003) [Pubmed]
  40. Transcorporal artificial urinary sphincter cuff placement in cases requiring revision for erosion and urethral atrophy. Guralnick, M.L., Miller, E., Toh, K.L., Webster, G.D. J. Urol. (2002) [Pubmed]
  41. Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system. Ning, S., Yu, N., Brown, D.M., Kanekal, S., Knox, S.J. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. (1999) [Pubmed]
  42. Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Iwamiya, T., Sawada, S., Ohta, Y. Cancer Chemother. Pharmacol. (1994) [Pubmed]
 
WikiGenes - Universities